After paying $100 million in 2013 for the option to buy Boston-based Acetylon Pharmaceuticals and then passing on a deal this August, Celgene purchased part of the cancer drug developer on Friday for an undisclosed sum. Privately-held Acetylon, which has 40 employees, said that it had been acquired by Celgene (Nasdaq: CELG).